Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | GPR3 | P46089 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | MPI | P34949 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | GALR1 | P47211 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4252848 | 0.83 | ALDH1A1 (0.36) | — | |
| SCHEMBL3147185 | 0.83 | GPR3 (0.50) | PIM1PIM2CHRM2CHRM1CHRM3 | |
| SCHEMBL2091935 | 0.81 | CHRM2 (0.47) | PIM1PIM2CHRM2CHRM1CHRM3 | |
| SCHEMBL30214321 | 0.81 | CHRM2 (0.47) | PIM1PIM2CHRM2CHRM1CHRM3 | |
| SCHEMBL7658787 | 0.79 | MAPT (0.42) | PIM1PIM2GPR3KIF11 | |
| SCHEMBL1526051 | 0.78 | GPR3 (0.42) | PIM1PIM2CHRM2CHRM1CHRM3 | |
| SCHEMBL31381747 | 0.77 | PIM1 (0.49) | PIM1PIM2CHRM2CHRM1CHRM3 | |
| SCHEMBL4293317 | 0.77 | PIM1 (0.49) | PIM1PIM2CHRM2CHRM1CHRM3 | |
| SCHEMBL3146332 | 0.75 | GPR3 (0.44) | PIM1PIM2CHRM2CHRM1CHRM3 | |
| SCHEMBL29139054 | 0.75 | KMT2A (0.43) | CHRM2CHRM1CHRM3EGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551846-A1 | AZABICYCLIC SPIROETHER DERIVATIVES AS RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004031191-A1 | AZABICYCLIC SPIROETHER DERIVATIVES AS RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| US-6479486-B2 | ANTIDEPRESSANTS, ANALGESICS | MERCK SHARP & DOHME LTD. (GB) | 2002-11-12 | — | — | US | disclosed |
| US-20020147207-A1 | AZABICYCLIC SPIROETHER DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147207-A1 | AZABICYCLIC SPIROETHER DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | GLRA1, GLRA2, CCKBR | PIM1 3248/4885PIM2 2660/4885CHRM2 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.